Elsevier

Journal of Controlled Release

Volume 149, Issue 3, 10 February 2011, Pages 307-313
Journal of Controlled Release

Release and bioactivity of PACA nanoparticles containing D-Lys6-GnRH for brushtail possum fertility control

https://doi.org/10.1016/j.jconrel.2010.10.029Get rights and content

Abstract

Poly(ethylcyanoacrylate) (PECA) nanoparticles containing the chemical sterilitant D-Lys6-GnRH were prepared by an in situ interfacial polymerization technique. Their potential as a peroral delivery system for biocontrol of the brushtail possum, a major pest species in New Zealand, was evaluated. Peptide release from resulting particles was studied in vitro in artificial gastric juice (AGJ), simulated intestinal fluids (SIF) and brushtail possum plasma. The nanoparticles released a small fraction of bioactive over 6 h in AGJ and SIF (< 5%), while staying intact and retaining fractions of intact D-Lys6-GnRH. In contrast, 60% of D-Lys6-GnRH was released after 1 h in possum plasma. The nanoparticles were also administered in vivo into the caecum of brushtail possums. A significant biological response, measured as an increase in plasma luteinizing hormone (LH), was evident 10 min after administration. This demonstrates not only that PECA nanoparticles were able to facilitate the uptake of D-Lys6-GnRH from the caecum into systemic circulation but also that sufficient bioactive peptide reached the pituitary to exert a significant LH response following GnRH receptor mediated endocytosis. Hence, it can be concluded that PECA nanoparticles comprise a promising formulation strategy for the peroral delivery of the chemical sterilitant D-Lys6-GnRH to the brushtail possum in New Zealand.

Introduction

The common brushtail possum (Trichosurus vulpecula) is a marsupial herbivore native to Australia that has become a pest species in New Zealand. The brushtail possum causes significant damage to native flora and fauna and is a reservoir for Mycobacterium bovis, the bacterium causing bovine tuberculosis [1]. Current methods of control (poisoning, shooting and trapping) have the disadvantage that they lack target specificity and humaneness, and they have failed to reduce the population of brushtail possums long term. The most publicly accepted strategy of possum population control is reducing their fertility [2]. Fertility control agents are likely to be protein and peptide bioactives [3], such as the neurohormone gonadotropin releasing hormone (GnRH), a key compound in the regulation of reproduction. D-Lys6-GnRH is a potent GnRH agonist and may be employed as a regulatory hormone causing a downregulation of GnRH receptors and desensitization of pituitary gonadotroph cells. Alternatively, GnRH may be used as a toxin conjugate, such as the GnRH-PAP (pokeweed antiviral protein) conjugate, which is able to target gonadotropin producing cells specifically and cause cell death [1], [4].

Any form of biocontrol requiring the individual handling of the animal is not feasible for wildlife. Self disseminating delivery systems (e.g. genetically modified viruses) raise safety concerns considering the proximity of New Zealand to Australia's protected marsupials [5]. In contrast, nondisseminating systems are safer but require aided delivery via bait and include carriers such as bacterial ghosts [6], [7], virus like particles (VLPs) [1] and pharmaceutical polymeric nanocarriers [3]. Bacterial ghosts and VLPs largely retain their immunogenicity and so appeal as a delivery system for immunocontraceptives. Chemical sterilitants, such as GnRH derivatives, however, are direct acting and should avoid the immune system. Pharmaceutical nanocarriers, such as poly(alkylcyanoacrylate) (PACA) nanoparticles can be prepared not only to avoid the immune system but also to protect the bioactive and facilitate the uptake in the gut, while maintaining the bioactivity of the drug [8], [9], [10], [11]. Furthermore, PACA nanoparticle formulations are easy to scale up, reproducible and affordable [12].

In situ loading of protein and peptide bioactives into PACA nanoparticles prepared by interfacial polymerization results in nanocapsules that confine the bioactive to the aqueous core and the polymer wall [13], [14]. High entrapment efficiencies are reported for proteins and peptides [13], [15], [16]; however, they are accompanied by low release rates of drug in the absence of esterases [17], [18]. Previously, we have demonstrated the covalent interference of some protein and peptide drugs, including D-Lys6-GnRH, during the polymerization process, which may explain the low release of bioactive observed in some studies [19], [20]. The sustained release of bioactive via the bioerosion of the polymer material has previously been suggested for peptide copolymerized PACA nanoparticles in the presence of esterases and rat plasma [21]. Whether or not peptide released from copolymerized PACA nanoparticles is still bioactive has been investigated only in a few studies. Gibaud et al. [17] demonstrated that the bioactivity of recombinant human granulocyte colony stimulating factor (rhG-CSF) in situ polymerized with PACA nanoparticles was lost. However, some authors have suggested that, despite the covalent association of proteins and peptides with PACA polymer, the in vivo bioactivity was maintained [18], [22]. Tasset et al. [18] demonstrated the hypocalcemic effect of i.v. administered calcitonin-loaded PACA nanoparticles was equivalent to the an i.v. dose of free drug. Peptide copolymerized systems may maintain their bioactivity if the bioactive site remains unobstructed and the folding of the bioactive is unaffected by the modification. For D-Lys6-GnRH, we have demonstrated that the modification occurs at the histidine residue [20], which is involved in receptor binding [23].

The aim of this study was to investigate the potential of PACA nanoparticles to deliver the fertility control agent D-Lys6-GnRH to a wild target species, the brushtail possum, and induce a biological response. Poly(ethylcyanoacrylate) (PECA) nanoparticles containing D-Lys6-GnRH were characterized in vitro for the amount of peptide released under physiological conditions. The in vivo bioactivity, measured as the plasma concentration of luteinizing hormone, was also determined following intracaecal administration in the brushtail possum.

Section snippets

Materials

D-Lys6-GnRH (p-Glu-His-Trp-Ser-Tyr-Lys6-Leu-Arg-Pro-GlyNH2) was purchased from PolyPeptide Laboratories (Torrance, CA, USA). Ethyloleate GPR was sourced from BDH Laboratory Supplies (Poole, England) and surfactants sorbitan monolaurate (Crill 1™) and ethoxy 20 sorbitan mono-oleate (Crillet 4™) were kindly provided by BTB Chemicals (Auckland, New Zealand). The monomer ethylcyanoacrylate (ECA) (Sicomet 40) was kindly donated by Henkel Loctite (Hannover, Germany). Sodium chloride 0.9%,

Physicochemical characterization of PECA nanoparticles containing D-Lys6-GnRH

PECA nanoparticles in situ loaded with D-Lys6-GnRH were on average 190 ± 0.5 nm in size with a polydispersity index of 0.077 ± 0.005 and a zeta potential of + 8.78 ± 0.183 mV. This is in consensus with our previous work [20]. The positive zeta potential gives a clear indication of the contribution of the positively charged peptide to the overall net charge of the otherwise negatively charged PECA nanoparticles either via the adsorption or copolymerization of peptide. The entrapment efficiency for D-Lys6

Conclusions

PECA nanoparticles comprise a feasible formulation strategy for the peroral delivery of the chemical sterilitant D-Lys6-GnRH to a target species, the brushtail possum. PECA nanoparticles in situ loaded with D-Lys6-GnRH showed little release (< 5%) of bioactive in AGJ and SIF, while the particles stayed intact over the duration of 6 h (TEM) and retained large fractions of intact peptide (MALDI TOF MS). In contrast, about 60% of D-Lys6-GnRH was released within 1 h when incubated in the presence of

Acknowledgements

The study was funded by FRST (Foundation for Research, Science and Technology), New Zealand. Acknowledgement is given to AgResearch Invermay New Zealand for their help with the animal experiments (Euan Thompson and Taryn Skinner) and analysis of blood samples (Shirley Martin), the Microscopy Unit (Department of Anatomy and Physiology, University of Otago) for their support with TEM imaging and Dr. Torsten Kleffmann (Centre for Protein Research, Department of Biochemistry, University of Otago)

References (47)

  • K. Biemann

    Nomenclature for peptide fragment ions (positive-ions)

    Method Enzymol.

    (1990)
  • M. Liang et al.

    Increasing entrapment of peptides within poly(alkylcyanoacrylate) nanoparticles prepared from water-in-oil microemulsions by copolymerization

    Int. J. Pharm.

    (2008)
  • D. Scherer et al.

    Influence of enzymes on the stability of poly(butylcyanoacrylate) nanoparticles

    Int. J. Pharm.

    (1994)
  • A.M. Hillery et al.

    Co-polymerised peptide particles (CPP)1: Synthesis, characterisation and in vitro studies on a novel oral nanoparticulate delivery system

    J. Control. Release

    (1996)
  • P. Couvreur et al.

    Adsorption of antineoplastic drugs to poly(alkylcyanoacrylate) nanoparticles and their release in calf serum

    J. Pharm. Sci.

    (1979)
  • P. Cowan

    Biological control of possums: Prospects for the future

  • P.E. Cowan

    Possum biocontrol: Prospects for fertility regulation

    Reprod. Fertil. Dev.

    (1996)
  • A. McDowell et al.

    Application of pharmaceutical drug delivery for biological control of the common brushtail possum in New Zealand: A review

    Wildl. Res.

    (2006)
  • K. Sabeur et al.

    Effect of GnRH conjugated to pokeweed antiviral protein on reproductive function in adult male dogs

    Reproduction

    (2003)
  • B. Gilna et al.

    Dangers of New Zealand possum biocontrol research to endogenous Australian fauna

    Conserv. Biol.

    (2005)
  • P. Couvreur et al.

    Nanocapsule technology: A review

    Crit. Rev. Ther. Drug

    (2002)
  • A. Graf et al.

    Poly(alkycyanoacrylate) nanoparticles for enhanced delivery of therapeutics: Is there real potential?

    Expert Opin. Drug Deliv.

    (2009)
  • C. Vauthier et al.

    Developing nanoparticle drug carriers

    Pharm. Technol. Eur.

    (2007)
  • Cited by (20)

    • Nano-based smart pesticide formulations: Emerging opportunities for agriculture

      2019, Journal of Controlled Release
      Citation Excerpt :

      Nanomaterials have novel physical, chemical, and mechanical properties (through conversion from their bulk forms), and they can overcome a number of limitations inherent in existing products (e.g., in terms of cost, fabrication strategies, functionality, and overall performance). As such, this emerging technology opened up a wide array of opportunities in diverse fields including medicine, food processing, agriculture, pharmaceuticals, materials science, electronics, and energy technologies [22–28]. For instance, nanotechnology holds the potential to revolutionize agriculture by balancing crop nutrients against their deficit or surplus values, monitoring water quality, seed treatment, pest control, germination, pesticide and fertilizer delivery, detection of toxic agro-chemicals, and reducing the toxic effects of plant protection products.

    • Advances on the formulation of proteins using nanotechnologies

      2017, Journal of Drug Delivery Science and Technology
    • Lipid-based nanocarriers for oral peptide delivery

      2016, Advanced Drug Delivery Reviews
    • Molecular characterization of kisspeptin gene and effect of nano-encapsulted kisspeptin-10 on reproductive maturation in Catla catla

      2016, Domestic Animal Endocrinology
      Citation Excerpt :

      Our results on sustained surge of hormonal levels over a period of 12 h corroborate the study of Mananos et al [44] in which enhanced reproductive output (milt production) was observed in spermiating males of D labrax in response to controlled release of GnRH analog. Kafka et al [45] showed that sufficient therapeutic levels of GnRH-loaded nanoparticles were achieved from drug loaded nanoparticles. Paclitaxel-loaded FSH conjugated nanoparticles showed significantly anti-cell proliferative and anti-tumor effects in time-dependent manner when compared with naked paclitaxel [46].

    • A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives

      2016, Saudi Pharmaceutical Journal
      Citation Excerpt :

      It can be smoothly functionalized for off opsonisation, and therefore has shown reduced toxicity towards the non-target areas (peripheral tissues) (Chan et al., 2010). Kafka et al. (2011) investigated the in vitro and in vivo studies of gonadotropin releasing hormone-loaded nanoparticles. Different in vitro conditions (artificial gastric juice, simulated intestinal fluid and brushtail possum plasma) were studied, and it was found that less than 5% of the hormone was released over 6 h in artificial gastric juice and simulated intestinal fluid, and 60% of it was released in brushtail possum tail plasma over 1 h.

    View all citing articles on Scopus
    1

    Present address: Coriolis Pharma, Am Klopferspitz 19, 82152 Martinsried, Germany.

    View full text